FDA Peptide Reclassification 2026: What Researchers Want The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy 503A vs. 503B Epicur Pharma A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read